Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

The company expanded its pipeline with SNDX-4321, a novel mutant-selective, allosteric EGFR inhibitor targeting NSCLC patient populations with significant unmet needs. While no efficacy, safety, or timeline data were provided, the addition supports a positive platform expansion story for future development.

Analysis

The company expanded its pipeline with SNDX-4321, a novel mutant-selective, allosteric EGFR inhibitor targeting NSCLC patient populations with significant unmet needs. While no efficacy, safety, or timeline data were provided, the addition supports a positive platform expansion story for future development.